Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy

Inclusion Criteria: * ① Possible or very likely CAA-ICH; * Within 7 days of onset; ③ Primary supratentorial intracerebral hemorrhage (bleeding volume ≤40ml); * GCS≥8 points; * NIHSS score ≤25 points; ⑥50≤age≤90 years old; ⑦ Gender is not limited; ⑧ The subject or their legal representative gives informed consent and signs the informed consent form. Exclusion Criteria: * Those who are known to be allergic to the components of the traditional Chinese medicine compound used in the experiment; * It is known that after treatment with vascular malformations, aneurysms, coagulation disorders, anticoagulant or antiplatelet drugs, Intracranial conditions caused by clear etiologies such as thrombolytic therapy, post-infarction hemorrhage transformation, hematological diseases, moyamoya disease, etc; * Patients with traumatic intracranial hemorrhage; * Patients with active peptic ulcers or other clear tendencies of rebleeding; * Patients with severe liver or kidney dysfunction (Note: Severe liver dysfunction is defined as ALT or AST being greater than. ⑥ Those who have received or are planning to undergo surgical treatment; ⑦ Those who suffer from other life-threatening serious diseases and have an expected survival time of less than six months; ⑧ Other conditions that significantly limit the evaluation of neurological function, prevent the completion of cranial magnetic resonance imaging, or affect the follow-up of patient; ⑨ Pregnant women, those planning to become pregnant or lactating women; ⑩Those who are currently participating in other interventional clinical trials.